SSA
IBRX icon

Schonfeld Strategic Advisors’s ImmunityBio IBRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
+54,092
New +$409K ﹤0.01% 1844
2026
Q1 		– Sell
-44,780
Closed -$88.7K – 2429
2025
Q4 		$88.7K Sell
44,780
-4,678
-9% -$10.6K ﹤0.01% 1831
2025
Q3 		$122K Buy
+49,458
New +$127K ﹤0.01% 2009
2024
Q3 		– Sell
-34,626
Closed -$219K – 2204
2024
Q2 		$219K Buy
+34,626
New +$228K ﹤0.01% 1789
2023
Q2 		– Sell
-79,100
Closed -$144K – 2301
2023
Q1 		$144K Sell
79,100
-76,103
-49% -$237K ﹤0.01% 1628
2022
Q4 		$787K Buy
+155,203
New +$852K 0.01% 1274
2020
Q4 		– Sell
-125,800
Closed -$873K – 1698
2020
Q3 		$873K Buy
125,800
+77,982
+163% +$777K 0.02% 736
2020
Q2 		$588K Buy
+47,818
New +$270K 0.02% 748

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Schonfeld Strategic Advisors's IBRX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in ImmunityBio (IBRX) in Q2 2026: 54,092 shares worth $474K. The stake represents ﹤0.01% of the portfolio and ranks #1844 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in IBRX as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in IBRX in Q2 2020 and has held it in 8 quarters since. The position peaked at $873K in Q3 2020. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Schonfeld Strategic Advisors held 54,092 shares of ImmunityBio worth $474K as of Q2 2026.
  • ImmunityBio was a new Schonfeld Strategic Advisors position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1844 holding.
  • Schonfeld Strategic Advisors first reported a position in ImmunityBio in Q2 2020 and has held it in 8 quarters since.
  • Schonfeld Strategic Advisors's ImmunityBio position peaked at $873K in Q3 2020.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.